Comparative Efficacy and Acceptability of Interventions for Major Depression in Older Persons: Protocol for Bayesian Network Meta-Analysis

Total Page:16

File Type:pdf, Size:1020Kb

Comparative Efficacy and Acceptability of Interventions for Major Depression in Older Persons: Protocol for Bayesian Network Meta-Analysis Open Access Protocol BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018. Downloaded from Comparative efficacy and acceptability of interventions for major depression in older persons: protocol for Bayesian network meta-analysis Tau Ming Liew,1,2,3 Cia Sin Lee4 To cite: Liew TM, Lee CS. ABSTRACT Strengths and limitations of this study Comparative efficacy and Introduction Major depression is a leading cause of acceptability of interventions disability and has been associated with adverse effects ► This systematic review and meta-analysis will for major depression in in older persons. While many pharmacological and non- older persons: protocol provide a comprehensive summary on the efficacy pharmacological interventions have been shown to be for Bayesian network and acceptability of all available interventions for effective to address major depression in older persons, meta-analysis. BMJ Open major depression in older persons. there has not been a meta-analysis that consolidates all the 2018;8:e019819. doi:10.1136/ ► The results will provide the highest level of evidence available interventions and compare the relative benefits bmjopen-2017-019819 to inform clinicians on the best choice of treatment of these available interventions. In this study, we aim to ► Prepublication history for from among the many available pharmacological conduct a systematic review and network meta-analysis this paper is available online. and non-pharmacological interventions. to compare the efficacy and acceptability of all the known To view these files, please visit ► This protocol has been developed in accordance pharmacological and non-pharmacological interventions for the journal online (http:// dx. doi. with the Preferred Reporting Items for Systematic major depression in older persons. org/ 10. 1136/ bmjopen- 2017- Reviews and Meta-analyses Protocols statement and 019819). Methods and analysis We will search Medline, Embase, has been registered with International Prospective PsycINFO, Cumulative Index to Nursing and Allied Health, Register of Systematic Reviews . Cochrane Central Register of Controlled Trials and references Received 27 September 2017 ► The overall quality of evidence will be assessed of other review articles for articles related to the keywords Revised 23 November 2017 using the Grading of Recommendations Assessment, of ‘randomised trial’, ‘major depression’, ‘older persons’ and Accepted 29 November 2017 Development and Evaluation approach. ‘treatments’. Two reviewers will independently select the ► This systematic review will be limited to studies eligible articles. For each included article, the two reviewers http://bmjopen.bmj.com/ which are reported in English language and have will independently extract the data and assess the risk of been peer reviewed. bias using the Cochrane revised tool for risk of bias. Bayesian network meta-analyses will be conducted to pool the depression scores (based on standardised mean difference) 3 and the all-cause discontinuation across all included medical comorbidities, with reported rates studies. The ranking probabilities for all interventions will of up to 5% in community-dwelling older 3–5 3 6 be estimated and the hierarchy of each intervention will be persons, 5%–10% in primary care and summarised as surface under the cumulative ranking curve as high as 37% after critical care hospitalisa- (SUCRA). Meta-regression and sub-group analyses will also tions.3 7 Major depression has a significant on September 28, 2021 by guest. Protected copyright. be performed to evaluate the effect of study-level covariates. impact on the older populations and has been The quality of the evidence will be assessed using the linked to higher risk of suicide,4 myocardial Grading of Recommendations Assessment, Development and infarction,8 stroke,9 all-cause mortality4 10 and Evaluation approach. increasing health services use.4 Ethics and dissemination The results will be disseminated Many of the interventions for major through conference presentations and peer-reviewed 1 Department of Geriatric publications. They will provide the consolidated evidence to depression in older persons have had recent Psychiatry, Institute of Mental inform clinicians on the best choice of intervention to address meta-analyses confirming their efficacy when Health, Singapore major depression in older persons. compared with control groups. These include 2Psychotherapy Unit, Institute of 11–14 PROSPERO registration number CRD42017075756. antidepressants, cognitive behavioural Mental Health, Singapore 15 16 3 therapy, problem-solving therapy, psycho- Saw Swee Hock School 17–19 of Public Health, National logical interventions in general and University of Singapore INTRODUCTIOn the various forms of non-pharmacological 4SingHealth Polyclinics, Rationale interventions.20–22 However, none of the Singapore Major depression has been identified by meta-analyses had compared all the phar- Correspondence to the WHO as one of the leading cause of macological and non-pharmacological inter- 1 2 Dr Tau Ming Liew; disability globally. In older persons, its ventions together to demonstrate the relative tau_ ming_ liew@ imh. com. sg prevalence rates rise with the increase in benefits of each intervention. It is unknown Liew TM, Lee CS. BMJ Open 2018;8:e019819. doi:10.1136/bmjopen-2017-019819 1 Open Access BMJ Open: first published as 10.1136/bmjopen-2017-019819 on 21 January 2018. Downloaded from whether the different types of pharmacological and We will include studies with non-pharmacological inter- non-pharmacological interventions have comparable effi- ventions, including but not limited to28–30: cacy and are equally suitable for older persons with major ► psychological interventions such as cognitive behav- depression. ioural therapy, problem-solving therapy, interper- sonal therapy, family interventions or psychodynamic Objectives therapy; In this study, we aim to conduct a systematic review ► procedural interventions such as electroconvulsive and network meta-analysis to compare the efficacy and therapy, transcranial magnetic stimulation, transcra- acceptability of all the available pharmacological and nial direct-current stimulation or bright light therapy. non-pharmacological interventions for major depression We will also include studies which reported on combi- in older persons. The use of network meta-analysis allows nations of any of these pharmacological and non-pharma- us to pool the evidence on various interventions and rank cological interventions. their benefits relative to each other.23 It also allows us to We will exclude studies which focused primarily on conduct indirect comparison of the different interven- health service models of care but were not related to any tions, even when there is no direct evidence in the litera- modality of intervention, such as studies which evaluated ture to allow head-to-head comparisons. the effectiveness of home treatment, training of general practitioners, multidisciplinary approach or stepped-care approach. METHODS AND ANALYSIS This protocol is developed in accordance with the Comparators Preferred Reporting Items for Systematic Reviews and We will accept control conditions such as placebo inter- Meta-analyses (PRISMA) statement.24 25 It has also vention, waiting list, treatment as usual, as well as no been registered with the International Prospective intervention. We will also include studies with active Register of Systematic Reviews (registration number comparators such as those which compare between two CRD42017075756). different interventions within the same studies. Outcomes Eligibility criteria We will only include a study if it reports the depression Participants and settings scores or the all-cause discontinuation in each study arm We will include studies which recruited participants who following intervention. were: ► 60 years old and above; Study designs and publication types ► diagnosed with major depression based on formal We will only include randomised controlled trials (RCTs), http://bmjopen.bmj.com/ criteria by the Diagnostic and Statistical Manual of which aimed to demonstrate the superiority of a treat- Mental Disorders or International Classification of ment to another (also known as superiority trials) and Diseases; will not include equivalence or non-inferiority trials. ► having a current episode of major depression (ie, the The following study designs or publication types will also participants were symptomatic and not in remission be excluded: qualitative studies, observational studies, at the point of recruitment and the intervention was meta-analyses, case reports, case series, ecological studies not intended primarily for the prevention of future and policy papers. We intend to include only higher quality relapses). evidence and hence will exclude non-randomised trials on September 28, 2021 by guest. Protected copyright. We will exclude studies which recruited participants and publications which were not peer-reviewed (such as with treatment-resistant depression, subthreshold depres- conference proceedings, letters and comments). sion, bipolar depression, depression in dementia or psychotic depression. We will not include maintenance Language and time frame studies for major depression as such studies primarily We will only include studies which are reported in the focused on the prevention of relapses in participants who English language. Apart from that, we do not impose any had been asymptomatic or in remission at the point of time
Recommended publications
  • Still the Leading Antidepressant After 40
    BRITISH JOURNAL OF PSYCHIATRY "2001), 178, 129^144 REVIEW ARTICLE Amitriptyline vv.therest:stilltheleading METHOD Inclusion criteria antidepressant after 40 years of randomised All RCTs comparing amitriptyline with any y other tricyclic,heterocyclic or SSRI were in- controlled trials cluded. Crossover studies were excluded. Studies adopting any criteria to define CORRADO BARBUI and MATTHEW HOTOPF patients suffering from depression were included; a concurrent diagnosis of another psychiatric disorder was not considered an exclusion criterion. Trials in patients with depression with a concomitant medical ill- Background Tricyclic antidepressants Amitriptyline is one of the first `reference' ness were not included in this review. have similar efficacy and slightly lower tricyclic antidepressants TCAs). Over the past 40 years a number of newer tricyclics, tolerability than selective serotonin Search strategy heterocyclics and selective serotonin re- Relevant studies were located by searching reuptakeinhibitorsreuptake inhibitors SSRIs).However, uptake inhibitors SSRIs) have been intro- the Cochrane Collaboration Depression, there are no systematic reviews assessing duced Garattini et aletal,1998). Despite Anxiety and Neurosis Controlled Trials several large systematic reviews comparing amitriptyline, the reference tricyclic drug, Register CCDANCTR). This specialised tricyclics and SSRIs there is no clear agree- vv. other tricyclics and SSRIs directly. register is regularly updated by electronic ment over first-line treatment of depression Medline,Embase,PsycINFO,LILACS, SongSong et aletal,1993; Anderson & Tomenson, Aims ToreviewTo review the tolerability and Psyndex,CINAHL,SIGLE) and non-electro- 1995; Montgomery & Kasper,1995; efficacy of amitriptyline inthe nicnicliterature searches. The register was HotopfHotopf et aletal,1996; Canadian Coordinating management of depression. searched using the following terms: Office for Health Technology Assessment, AMITRIPTYLIN**AMITRIPTYLIN oror AMITRILAMITRIL oror ELA-ELA- 19971997aa).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0065218A1 Migeon Et Al
    US 2005.0065218A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0065218A1 Migeon et al. (43) Pub. Date: Mar. 24, 2005 (54) UTILIZATION OF ALVERINE, ALONE OR IN (30) Foreign Application Priority Data COMBINATION WITH TRICYCLC ANTDEPRESSANT OR A SPECIFIC Jun. 13, 2003 (FR).............................................. O307176 SEROTONIN REUPTAKE INHIBITOR FOR Apr. 30, 2004 (FR).............................................. O404639 THE TREATMENT OF DEPRESSION Publication Classification (76) Inventors: Jacques Migeon, Seattle, WA (US); Frederic Revah, Paris (FR) (51) Int. C.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - A61K 31/137 (52) U.S. Cl. .............................................................. 514/649 Correspondence Address: SESD LARDNER (57) ABSTRACT 3000 KSTREET NW WASHINGTON, DC 20007 (US) The present invention relates to the utilization of Alverine or its metabolites, alone or in combination with a tricyclic (21) Appl. No.: 10/866,079 antidepressant or a Specific Serotonin reuptake inhibitor, for the preparation of pharmaceutical compositions for the (22) Filed: Jun. 14, 2004 treatment of depression. 80 120 OO 8 O 6 O 40 20 t Excipicnts Alverine Alverine Alverine Imiprannine (1% methylcellulose) Citate Citrate Citrate 10 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg Patent Application Publication Mar. 24, 2005 Sheet 1 of 4 US 2005/0065218 A1 Excipients Alverine Alveline Alveline Inipramine (1% methylcellulose) Citrate Citrate Citrate 10 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg Fi gure US 2005/0065218A1 Imipramine 30 mg/kg Figure 2 Patent Application Publication Mar. 24, 2005 Sheet 3 of 4 US 2005/0065218A1 20 Vehicle + Whicule -- Averine Alvérine Vehicule + Alverine Vehicule imipramine 3 ring/kg it 3 mg/kg t- Impramine 10 mg/kg + 3 mg/kg Wellicule imipramine 10 mg/kg Vehicule 3 mg/kg Figure 3 Patent Application Publication Mar.
    [Show full text]
  • 2019 Instrumentation and Consumable Catalog 2 INSTRUMENTATION and CONSUMABLE CATALOG
    PRODUCT CATALOG 2019 Instrumentation and Consumable Catalog 2 INSTRUMENTATION AND CONSUMABLE CATALOG Resolvex® A200 Part Numbers: A200 96: 253-1160 Resolvex® A200 96 Resolvex A200 Standalone work station for automated sample preparation. The compact benchtop offers the one stop solution for automating sample preparation utilizing creation of multiple work flows, and programmable dispensing of up to 11 solvents. Along with its innovative positive pressure system leading to clean samples, improving accuracy, throughput and enhancing the Life time of your analytical instrument. The A200 comes with an easy to use touch screen interface allowing for easy set up of multiple work flows. In addition the light curtain safety feature will release gas pressure when manifold is activated to prevent any injuries. INSTRUMENTATION AND CONSUMABLE CATALOG 3 Resolvex® A100 Part Numbers: A100 96: 253-0019 A100 48: 253-0014 Resolvex® A100 Standalone work station for automated sample preparation. The compact benchtop offers the one stop solution for automating sample preparation utilizing creation of multiple work flows, and programmable dispensing of up to 11 solvents. Along with its innovative positive pressure system leading to clean samples, improving accuracy, throughput and enhancing the Life time of your analytical instrument. The A100 comes in 96 and 4 configuration allowing for for automated Work Flow solutions in multiple SPE formats. 4 INSTRUMENTATION AND CONSUMABLE CATALOG Resolvex® M10 96/M10 96 XT/M10 48 Part Numbers: M10 96 XT: 288-0006 M10 96: 288-0001 M10 48: 289-0004 Resolvex® M10 Standalone work station for Positive Pressure solid phase extraction. The manual Resolvex M10 48 and 96 are positive pressure manifold for 1, 3, and 6 ml cartridges, or 1ml 96 well plates.
    [Show full text]
  • Gps' Drug Treatment for Depression by Patients' Educational Level
    RESEARCH GPs’ drug treatment for depression by patients’ educational level: registry- based study Anneli Borge Hansen, MD1,2*, Valborg Baste, MSc. Statistics, PhD1, Oystein Hetlevik, MD, PhD1,2, Inger Haukenes, MSc. Philosophy, PhD1,2, Tone Smith- Sivertsen, MD, PhD1,3, Sabine Ruths, MD, PhD1,2 1Research Unit for General Practice, NORCE Norwegian Research Centre, Bergen, Norway; 2Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; 3Division of Psychiatry, Haukeland University Hospital, Bergen, Norway Abstract Background: Antidepressant drugs are often prescribed in general practice. Evidence is conflicting on how patient education influences antidepressant treatment. Aim: To investigate the association between educational attainment and drug treatment in adult patients with a new depression diagnosis, and to what extent sex and age influence the association. Design & setting: A nationwide registry- based cohort study was undertaken in Norway from 2014– 2016. Method: The study comprised all residents of Norway born before 1996 and alive in 2015. Information was obtained on all new depression diagnoses in general practice in 2015 (primary care database) and data on all dispensed depression medication (Norwegian Prescription Database [NorPD]) 12 months after the date of diagnosis. Independent variables were education, sex, and age. Associations with drug treatment were estimated using a Cox proportional hazard model and performed separately for sex. *For correspondence: ahan@ Results: Out of 49 967 patients with new depression (61.6% women), 15 678 were dispensed drugs norceresearch. no (30.4% women, 33.0% men). Highly educated women were less likely to receive medication (hazard ratio [HR] = 0.93; 95% confidence interval [CI] = 0.88 to 0.98) than women with low education.
    [Show full text]
  • Still the Leading Antidepressant After 40 Years of Randomised Controlle
    BRITISH JOURNAL OF PSYCHIATRY "2001), 178, 129^144 REVIEW ARTICLE Amitriptyline vv.therest:stilltheleading METHOD Inclusion criteria antidepressant after 40 years of randomised All RCTs comparing amitriptyline with any y other tricyclic,heterocyclic or SSRI were in- controlled trials cluded. Crossover studies were excluded. Studies adopting any criteria to define CORRADO BARBUI and MATTHEW HOTOPF patients suffering from depression were included; a concurrent diagnosis of another psychiatric disorder was not considered an exclusion criterion. Trials in patients with depression with a concomitant medical ill- Background Tricyclic antidepressants Amitriptyline is one of the first `reference' ness were not included in this review. have similar efficacy and slightly lower tricyclic antidepressants TCAs). Over the past 40 years a number of newer tricyclics, tolerability than selective serotonin Search strategy heterocyclics and selective serotonin re- Relevant studies were located by searching reuptakeinhibitorsreuptake inhibitors SSRIs).However, uptake inhibitors SSRIs) have been intro- the Cochrane Collaboration Depression, there are no systematic reviews assessing duced Garattini et aletal,1998). Despite Anxiety and Neurosis Controlled Trials several large systematic reviews comparing amitriptyline, the reference tricyclic drug, Register CCDANCTR). This specialised tricyclics and SSRIs there is no clear agree- vv. other tricyclics and SSRIs directly. register is regularly updated by electronic ment over first-line treatment of depression Medline,Embase,PsycINFO,LILACS, SongSong et aletal,1993; Anderson & Tomenson, Aims ToreviewTo review the tolerability and Psyndex,CINAHL,SIGLE) and non-electro- 1995; Montgomery & Kasper,1995; efficacy of amitriptyline inthe nicnicliterature searches. The register was HotopfHotopf et aletal,1996; Canadian Coordinating management of depression. searched using the following terms: Office for Health Technology Assessment, AMITRIPTYLIN**AMITRIPTYLIN oror AMITRILAMITRIL oror ELA-ELA- 19971997aa).
    [Show full text]
  • Treatment Resistant Depression Clinic Clinician Referral Form
    Treatment Resistant Depression Clinic Clinician Referral Form Patient Date: Name: Contact DOB: Sex: No: Ref. By: Contact: **Treating Contact: Psychiatrist: Primary Please Include Copy of Patient’s Insurance Insurance Card (Front and Back) Provider: PSYCHIATRIC NOTES How long have you known this patient? Current Diagnosis/Diagnoses: Current/Target Symptoms Past History of ECT □NO □YES If YES, # of sessions: Type: □UL □BF □BT Dates: Past response: □excellent □good □fair □poor □unknown Past History of TMS □NO □YES If YES, # of sessions: Dates: Past response: □excellent □good □fair □poor □unknown Current Medications: Current Medical Problems Emory Treatment Resistant Depression Clinic Clinician Referral Form 10/07/15 Allergies Do we have permission to contact the patient? □NO □YES ADDITIONAL NOTES Clinical Impression : Please complete the attached medication history form Include a copy of the patient’s insurance card (front and back) Fax referral form to: 404 712 7436. Attn: Emory TRD Clinic If you have any questions, please contact: Taelar Johnson at 404 712 8732 Emory Treatment Resistant Depression Clinic Clinician Referral Form 10/07/15 Generic Date drug How many weeks drug Drug Class Name was tried Min. Dose Max Dose Dosage was taken? Was it helpful?/Side Effects TCA Adapin Doxepin 150mg/d 250mg/d Anafranil Clomipramine 150mg/d 250mg/d Asendin Amoxapine 150mg/d 250mg/d Endep/Elavil Amitriptyline 150mg/d 250mg/d Ludiomil Maprotiline 150mg/d 250mg/d Norpramin Desipramine 150mg/d 250mg/d Pamelor Nortyrptiline 75mg/d 125mg/d Sinequin Doxepin
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Info on Skin Testing
    Information on Skin Testing *Please review 1 week prior to testing* Your Doctor has ordered an allergy test for you. Your appointment has been made for: ___________________________________ at _______________________AM/PM at our (date) (time) _ Foulkstone / Limestone / Glasgow _ office. Skin tests are a method of testing for allergic reactions to substances, or allergens, in the environment. Our practice utilizes a test that involves no needles! We use a prick method which involves a series of small plastic applicators that carry a specific antigen which is placed on your arms. The types of allergens we test for include weeds, trees, grasses, molds, animal dander, dust mites and some foods. The testing will take 45 minutes. Please remember to wear comfortable clothing with short sleeves. Reactions can consist of itchy eyes, nose or throat, nasal congestion, runny nose, tightness in the throat or chest, wheezing, lightheadedness, hives or anaphylactic shock. Although this is very rare, our staff is fully prepared with emergency equipment and a physician is always on site. To ensure accurate testing results, certain medicines should be stopped 5 days prior to testing, although you should not stop medicines without talking to your prescribing physician. Medications that interfere with testing include but are not limited to: Antihistamines are medicines used to treat allergies, nausea, and dizziness. Many are found in over the counter cold medicines. They include, but are not limited to: ALAVERT / CLARITIN (LORATIDINE) DRAMAMINE (DIMENHYDRINATE)
    [Show full text]
  • Xinyu Zhou, Bin Qin, Craig Whittington, 2 David Cohen, 3 Yiyun
    Open Access Protocol Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: study protocol for a systematic review and network meta-analysis Xinyu Zhou,1 Bin Qin,1 Craig Whittington,2 David Cohen,3 Yiyun Liu,1 Cinzia Del Giovane,4 Kurt D Michael,5 Yuqing Zhang,1 Peng Xie1 To cite: Zhou X, Qin B, ABSTRACT et al Strengths and limitations of this study Whittington C, . Introduction: Depressive disorders are among the Comparative efficacy and most common psychiatric disorders in children and ▪ tolerability of first-generation This Bayesian network meta-analysis can inte- adolescents, and have adverse effects on their and newer-generation grate direct evidence with indirect evidence from antidepressant medications psychosocial functioning. Questions concerning the multiple treatment comparisons to estimate the for depressive disorders in efficacy and safety of antidepressant medications in the interrelations across all treatments. children and adolescents: treatment of depression in children and adolescents, ▪ We will comprehensively assess the efficacy, study protocol for led us to integrate the direct and indirect evidence tolerability, acceptability and suicide-related out- a systematic review and using network meta-analysis to create hierarchies of comes of first-generation and newer-generation BMJ network meta-analysis. these drugs. antidepressant medications for depression in Open 2015;5:e007768. Methods and analysis: Seven databases with children and adolescents. doi:10.1136/bmjopen-2015- PubMed, EMBASE, the Cochrane Library, Web of ▪ 007768 Several subgroup and sensitivity analyses will Science, CINAHL, LiLACS and PsycINFO will be address some clinically relevant questions. searched from 1966 to December 2013 (updated to ▪ This method comprehensively synthesises data ▸ Prepublication history for May, 2015).
    [Show full text]
  • Receptor Binding Profile of Quinupramine, a New Tricyclic Antidepressant
    Receptor Binding Profile of Quinupramine, a New Tricyclic Antidepressant Hirohiko SAKAMOTO*, **, Nobuharu YOKOYAMA*, **, Shigekatsu KOHNO* and Katsuya OHATA* *Department of Pharmacology , Kyoto Pharmaceutical University, Yamashina, Kyoto 607, Japan **Biochemical Division , Research Laboratories, Nippon Shoji Kaisha, Ltd., Ibaraki, Osaka 567, Japan Accepted August 17, 1984 Abstract-The receptor binding profile, composed of the K;-values measured in eight different receptor binding models using rat brain membranes, is reported for the new tricyclic antidepressant quinupramine, 10,11 -dihydro-5-(3-quinuclidinyl) 5H-dibenz[b, f]azepine, and three reference compounds with a tertiaryamine side chain. Quinupramine was found to possess high affinity for muscarinic cholinergic and histamine Ht receptor binding sites in rat brain, whereas its affinity for imipramine binding sites was only one seventieth that of imipramine. Receptor binding profiles of the reference compounds were almost similar to that of quinupramine , except in the case of imipramine binding sites. Tricyclic antidepressants are known to be clidinyl [phenyl-4-3H]benzilate (42 Ci/ inhibitors of norepinephrine and serotonin mmol), [pyridinyl-5-3H]pyrilamine (28 Ci/ reuptake into nerve terminals. This action was mmol) and [phenyl-4-3H]spiperone (17 Ci/ also believed to be responsible for their mmol) were purchased from Amersham , therapeutic effects and probably involved Buckinghamshire, England. [N-methyl-3H] presynaptic sites (1). In addition, recent imipramine hydrochloride (75 Ci/mmol) was reports suggest a direct interaction of tricyclic from New England Nuclear, Boston, MA , antidepressants with a variety of seemingly U.S.A. 3H-Ligands were stored at -20°C postsynaptic sites. These evidences have and diluted in standard assay buffer before been obtained through the interaction of use.
    [Show full text]
  • Tricyclic Antidepressants Versus
    Jørgensen et al. Syst Rev (2021) 10:227 https://doi.org/10.1186/s13643-021-01789-0 PROTOCOL Open Access Tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis Caroline Kamp Jørgensen1* , Sophie Juul1,2,3, Faiza Siddiqui1, Marija Barbateskovic1, Klaus Munkholm4, Michael Pascal Hengartner5, Irving Kirsch6, Christian Gluud1 and Janus Christian Jakobsen1,7 Abstract Background: Major depressive disorder is a common psychiatric disorder causing great burden on patients and societies. Tricyclic antidepressants are frequently used worldwide to treat patients with major depressive disorder. It has repeatedly been shown that tricyclic antidepressants reduce depressive symptoms with a statistically signifcant efect, but the efect is small and of questionable clinical importance. Moreover, the benefcial and harmful efects of all types of tricyclic antidepressants have not previously been systematically assessed. Therefore, we aim to investigate the benefcial and harmful efects of tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder. Methods: This is a protocol for a systematic review with meta-analysis that will be reported as recommended by Pre- ferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols, bias will be assessed with the Cochrane Risk of Bias tool—version 2, our eight-step procedure will be used to assess if the thresholds for clinical signifcance are crossed, Trial Sequential Analysis will be conducted to control random errors and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach.
    [Show full text]
  • A Database of Randomised Controlled Trials
    Zhang et al. BMC Psychiatry (2018) 18:162 https://doi.org/10.1186/s12888-018-1749-0 DATABASE Open Access Antidepressants for depressive disorder in children and adolescents: a database of randomised controlled trials Yuqing Zhang1,2†, Xinyu Zhou3†, Juncai Pu4, Hanping Zhang4, Lining Yang4, Lanxiang Liu4, Chanjuan Zhou1,2, Shuai Yuan4, Xiaofeng Jiang4 and Peng Xie1,2,4* Abstract Background: In recent years, whether, when and how to use antidepressants to treat depressive disorder in children and adolescents has been hotly debated. Relevant evidence on this topic has increased rapidly. In this paper, we present the construction and content of a database of randomised controlled trials of antidepressants to treat depressive disorder in children and adolescents. This database can be freely accessed via our website and will be regularly updated. Description: Major bibliographic databases (PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO and LiLACS), international trial registers and regulatory agencies’ websites were systematically searched for published and unpublished studies up to April 30, 2017. We included randomised controlled trials in which the efficacy or tolerability of any oral antidepressant was compared with that of a control group or any other treatment. In total, 7377 citations from bibliographical databases and 3289 from international trial registers and regulatory agencies’ websites were identified. Of these, 53 trials were eligible for inclusion in the final database. Selected data were extracted from each study, including characteristics of the participants (the study population, setting, diagnostic criteria, type of depression, age, sex, and comorbidity), characteristics of the treatment conditions (the treatment conditions, general information, and detail of pharmacotherapy and psychotherapy) and study characteristics (the sponsor, country, number of sites, blinding method, sample size, treatment duration, depression scales, other scales, and primary outcome measure used, and side-effect monitoring method).
    [Show full text]